| S4079 |
Ticagrelor
|
Ticagrelor (AZD6140, AR-C 126532XX) is the first reversibly binding oral P2Y12 receptor antagonist with Ki of 2 nM.
|
-
J Immunother Cancer, 2024, 12(11)e009805
-
Evid Based Complement Alternat Med, 2022, 2022:7941039
-
Am J Respir Crit Care Med, 2021, 10.1164/rccm.202009-3686OC
|
|
| S7705 |
A-438079 Hydrochloride
|
A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.
|
-
Redox Biol, 2024, 72:103154
-
Cells, 2023, 12(23)2696
-
Biomol Biomed, 2023, 23(5):825-837
|
|
| E1128 |
BzATP triethylammonium salt
|
BzATP triethylammonium salt acts as a P2X receptor agonist with pEC50s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively, also is potent at P2X7 receptors with EC50s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively.
|
|
|
| S1415 |
Clopidogrel (SR-25990C) Bisulfate
|
Clopidogrel (SR-25990C) Bisulfate is an oral, thienopyridine class antiplatelet agent.
|
-
Nat Commun, 2025, 16(1):7974
-
J Immunother Cancer, 2024, 12(11)e009805
-
Cell Mol Life Sci, 2024, 81(1):116
|
|
| S8725 |
A-804598
|
A-804598 is a selective P2X7R antagonist with high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) P2X7 receptors.
|
-
Immunobiology, 2025, 230(6):153119
-
Biol Pharm Bull, 2025, 48(5):657-671
-
J Cell Physiol, 2022, 10.1002/jcp.30685
|
|
| S3737 |
Cangrelor Tetrasodium
|
Cangrelor (AR-C69931MX) is a potent, competitive P2Y12 receptor inhibitor that is administered by intravenous infusion and rapidly achieves near complete inhibition of ADP-induced platelet aggregation.
|
-
J Immunother Cancer, 2024, 12(11)e009805
-
J Thromb Haemost, 2023, S1538-7836(23)00082-X
-
Food Funct, 2021, 10.1039/d1fo00531f
|
|
| S1258 |
Prasugrel
|
Prasugrel (Effient, Efient, Prasita,CS-747, LY640315,PCR 4099) is a thienopyridine ADP receptor (P2Y12) antagonist, used for the reduction of thrombotic cardiovascular events.
|
-
Oncol Lett, 2018, 15(5):6107-6114
-
J Toxicol Sci, 2017, 42(6):755-761
|
|
| S2855 |
MRS 2578
|
MRS2578 is a potent P2Y6 receptor antagonist with an IC50 of 37 nM, and exhibits insignificant activity at P2Y1, P2Y2, P2Y4, and P2Y11 receptors.
|
-
Ann Med, 2022, 54(1):1616-1626
-
Sci Rep, 2021, 11(1):15129
|
|
| S0826 |
A-740003
|
A-740003 is a potent, selective and competitive antagonist of P2X7 receptor with IC50 of 18 nM and 40 nM for rat and human P2X7 receptors, respectively. This compound potently blocks agonist-evoked IL-1β release and pore formation with IC50 of 156 nM and 92 nM in differentiated human THP-1 cells.
|
-
Am J Cancer Res, 2024, 14(2):585-600
-
Cell Rep, 2023, 42(7):112696
|
|
| S4637 |
Prasugrel Hydrochloride
|
Prasugrel hydrochloride (Prasugrel HCl, LY640315, PCR 4099 Hydrochloride) is a piperazine derivative and platelet aggregation inhibitor that is used to prevent thrombosis in patients with acute coronary syndrome.
|
-
J Immunother Cancer, 2024, 12(11)e009805
-
Oncol Lett, 2018, 15(5):6107-6114
|
|